BG Medicine, Inc. (BGMD) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 16, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerBG Medicine, Inc. (BGMD) trades at $0.0001. BG Medicine, Inc. is a diagnostics company focused on developing and commercializing cardiovascular diagnostic tests. Sector: Healthcare.
Price as of Sep 10, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for BGMD: BGMD does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates BGMD against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
BGMD: 1/2 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
BG Medicine, Inc. (BGMD) Healthcare & Pipeline Overview
BG Medicine, Inc. operates in the medical diagnostics sector, focusing on cardiovascular testing. Their core offerings, the BGM Galectin-3 and CardioSCORE tests, target unmet needs in identifying and managing cardiovascular risks. The company's small size and OTC listing present unique challenges and opportunities in a competitive market.
What Is the Investment Thesis for BGMD?
Investing in BG Medicine, Inc. presents a high-risk, high-reward scenario. The company's focus on cardiovascular diagnostics addresses a significant market need, given the prevalence of heart disease. However, its small market capitalization and OTC listing introduce substantial risks. The BGM Galectin-3 and CardioSCORE tests have the potential to generate revenue, but commercial success hinges on market adoption and reimbursement approvals. With a negative ROE of -902.6% and negative free cash flow, the company's financial stability is a concern. A key value driver is the successful commercialization and adoption of its diagnostic tests. Upcoming catalysts include potential partnerships, regulatory approvals, and expansion into new markets. Investors should carefully weigh the potential upside against the significant financial and operational risks.
Based on FMP financials and quantitative analysis
BGMD Key Highlights
Gross Margin of 67.8% indicates strong potential profitability if sales volume increases.
- Negative ROE of -902.6% reflects significant losses and inefficient use of equity.
- Market Cap of $0.00B indicates the company is a microcap stock with high volatility.
- Free Cash Flow of $-0.00B suggests the company is reliant on external funding.
- Beta of 83.31 indicates extreme volatility relative to the market.
Who Are BGMD's Competitors?
BGMD is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| A Agilent Technologies, Inc. | $142.65 | -1.45% | $40.3B | 795-pillar |
| TMO Thermo Fisher Scientific Inc. | $603.18 | -0.41% | $224B | 645-pillar |
| LUCY Innovative Eyewear, Inc. | $0.84 | -3.05% | $5.31M | — |
| FEMY Femasys Inc. | $2.74 | -3.18% | $8.27M | — |
| RGNT Regentis Biomaterials Ltd. | $1.96 | -2.49% | $13.8M | 645-pillar |
| ZJYL Jin Medical International Ltd. | $2.06 | -8.44% | $16.1M | 405-pillar |
| HBIO Harvard Bioscience, Inc. | $8.16 | +0.12% | $36.8M | — |
| MLSS Milestone Scientific Inc. | $0.43 | +3.85% | $38.4M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are BGMD's Key Strengths?
Specialized focus on cardiovascular diagnostics.
- Proprietary BGM Galectin-3 and CardioSCORE tests.
- Potential to address unmet medical needs.
- Established presence in the diagnostics market.
What Are BGMD's Weaknesses?
Small market capitalization and OTC listing.
- Negative ROE and free cash flow.
- Limited financial resources.
- Dependence on a small number of products.
What Could Drive BGMD Stock Higher?
Potential partnerships with hospitals or clinics to expand test utilization.
- Regulatory approvals for BGM Galectin-3 and CardioSCORE tests in new markets.
- Increasing awareness and adoption of Galectin-3 testing as a standard of care.
- Development of new diagnostic tests for other cardiovascular conditions.
- Integration of BG Medicine's diagnostic tests with telehealth platforms.
What Are the Key Risks for BGMD?
Competition from larger, more established players in the diagnostics market.
- Regulatory hurdles and reimbursement challenges for new diagnostic tests.
- Technological obsolescence of existing diagnostic technologies.
- Limited financial resources and dependence on external funding.
- Small market capitalization and OTC listing increasing volatility.
What Are the Growth Opportunities for BGMD?
- Expansion into European Markets: BG Medicine has the opportunity to expand its market reach into Europe, leveraging the established regulatory pathways and healthcare systems. The European cardiovascular diagnostics market is substantial, offering a significant revenue potential. Successful market entry would require strategic partnerships and regulatory approvals, which could take 1-2 years to materialize. This expansion could significantly increase the company's revenue base and global presence.
- Strategic Partnerships with Hospitals and Clinics: Forming strategic partnerships with hospitals and clinics can provide BG Medicine with access to a broader patient base and accelerate the adoption of its diagnostic tests. These partnerships can involve collaborative research, co-marketing agreements, and integration of BG Medicine's tests into clinical workflows. Securing several key partnerships within the next year could significantly boost sales and market penetration. This approach leverages existing healthcare infrastructure to drive growth.
- Development of New Diagnostic Tests: Investing in the development of new diagnostic tests for other cardiovascular conditions can expand BG Medicine's product portfolio and address additional unmet medical needs. This could involve exploring new biomarkers and developing innovative testing methodologies. The timeline for developing and commercializing new tests is typically 2-3 years, requiring significant R&D investment. A broader product portfolio can enhance the company's competitive position and revenue diversification.
- Increased Awareness and Adoption of Galectin-3 Testing: Increasing awareness and adoption of galectin-3 testing as a standard of care for heart failure management can drive demand for BG Medicine's BGM Galectin-3 test. This can be achieved through educational initiatives, clinical studies, and marketing campaigns targeting physicians and patients. A successful awareness campaign over the next 1-2 years could lead to increased test utilization and revenue growth. This strategy focuses on establishing the clinical value of the company's existing products.
- Telehealth Integration: Integrating BG Medicine's diagnostic tests with telehealth platforms can expand access to testing and improve patient outcomes. Telehealth solutions enable remote monitoring and management of cardiovascular conditions, creating opportunities for remote testing and data analysis. Integrating with telehealth providers within the next year could enhance the accessibility and convenience of BG Medicine's tests, driving adoption and revenue growth. This approach aligns with the growing trend of remote healthcare delivery.
What Are BGMD's Competitive Advantages?
- Proprietary diagnostic tests: BGM Galectin-3 and CardioSCORE are unique offerings.
- Focus on unmet medical needs: Addressing specific gaps in cardiovascular diagnostics.
- Established presence in cardiovascular testing: Building a reputation in the field.
- Intellectual property: Patents and trademarks protecting their diagnostic technologies.
What Does BGMD Do?
BG Medicine, Inc., established in 2000 and headquartered in Waltham, Massachusetts, is a diagnostics company specializing in the development and commercialization of cardiovascular diagnostic tests. Originally named Beyond Genomics, Inc., the company rebranded in 2004 to reflect its focus on medical solutions. BG Medicine aims to address unmet medical needs through innovative diagnostic tools in the United States, Europe, and internationally. Their primary products include the BGM Galectin-3 test, which measures galectin-3 levels in blood plasma or serum to assess heart failure risk, and the CardioSCORE test, designed to identify individuals at risk of cardiovascular events like heart attack and stroke. The company's diagnostic solutions are intended to aid clinicians in the early detection and management of cardiovascular diseases, a leading cause of mortality worldwide. BG Medicine operates within the broader medical instruments and supplies industry, competing with larger and more established players in the diagnostics market. The company's strategy involves developing and commercializing novel tests that offer improved accuracy and clinical utility compared to existing diagnostic methods.
What Products and Services Does BGMD Offer?
- Develop and commercialize cardiovascular diagnostic tests.
- Offer the BGM Galectin-3 test for assessing heart failure risk.
- Provide the CardioSCORE test for identifying individuals at risk of cardiovascular events.
- Focus on addressing unmet medical needs in cardiovascular disease management.
- Operate in the United States, Europe, and internationally.
- Provide diagnostic tools for early detection and management of cardiovascular diseases.
How Does BGMD Make Money?
- Generate revenue through the sale of diagnostic tests.
- Partner with hospitals and clinics for test utilization.
- Seek reimbursement from insurance companies and healthcare providers.
- Expand market reach through strategic partnerships and international expansion.
What Industry Does BGMD Operate In?
BG Medicine, Inc. operates within the medical instruments and supplies industry, a segment of the healthcare sector characterized by innovation and technological advancements. The cardiovascular diagnostics market is driven by the increasing prevalence of heart disease and the growing demand for early detection and personalized medicine. Competition is intense, with established players like Abbott and Roche dominating the market. BG Medicine, with its niche focus on galectin-3 testing and CardioSCORE, aims to carve out a market share by offering specialized diagnostic solutions. The industry is subject to stringent regulatory requirements and reimbursement policies, which can impact the commercial success of new diagnostic tests.
Who Are BGMD's Key Customers?
- Hospitals and clinics.
- Cardiologists and other healthcare professionals.
- Patients at risk of or diagnosed with cardiovascular diseases.
- Research institutions conducting cardiovascular studies.
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● Price is current
- ● No filing on record
- ● No analyst coverage
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 54 |
| 2026-08-26 | 54 |
| 2026-08-29 | 54 |
| 2026-09-01 | 54 |
| 2026-09-04 | 54 |
| 2026-09-07 | 54 |
| 2026-09-10 | 54 |
What changed?
The score has stayed at 54.
Over the same 18 days the stock moved +0.0%.
Company Profile
BG Medicine, Inc. operates in the Medical - Instruments & Supplies industry within the Healthcare sector. It is headquartered in Waltham, US. The company is led by CEO Stephen Hall. BGMD has traded publicly since 2011.
Financial Health
BG Medicine, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile.
Earnings Track Record
BG Medicine, Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 14.7% above estimates on average.
Insider Activity
The most recent 9 insider filings for BG Medicine, Inc. break down as 4 sales and 5 purchases. On net that is roughly 3K shares acquired (about $4K) — insiders putting money in tends to read as conviction.
BGMD Financials
Bull Case vs Bear Case
Bull Case
- Specialized focus on cardiovascular diagnostics.
- Proprietary BGM Galectin-3 and CardioSCORE tests.
- Potential to address unmet medical needs.
- Established presence in the diagnostics market.
Bear Case
- Small market capitalization and OTC listing.
- Negative ROE and free cash flow.
- Limited financial resources.
- Dependence on a small number of products.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
BGMD Latest News
-
Stocks That Hit 52-Week Lows On Monday
· Nov 25, 2019
BGMD Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for BGMD.
Price Targets
Wall Street price target analysis for BGMD.
BGMD MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for BGMD; grades run from A+ (80-100) to F (below 30).
BGMD OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that BG Medicine, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, minimal assets, or are undergoing financial distress. Investing in OTC Other stocks carries significant risks due to the lack of regulatory oversight and potential for fraud or manipulation. Unlike NYSE or NASDAQ-listed companies, OTC Other firms may not be required to adhere to strict listing standards or maintain a minimum share price.
- OTC Tier: OTC Other
- Limited liquidity and price volatility.
- Lack of regulatory oversight and financial transparency.
- Potential for fraud or manipulation.
- Uncertainty regarding the company's financial condition.
- Limited access to capital markets.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and regulatory approvals.
- Determine the company's capital structure and funding needs.
- Monitor news and press releases for any red flags.
- Consult with a qualified financial advisor.
- Established presence in the diagnostics market.
- Proprietary BGM Galectin-3 and CardioSCORE tests.
- Focus on addressing unmet medical needs.
- Company has been in operation since 2000.
- Headquarters located in Waltham, Massachusetts.
BGMD Healthcare Stock FAQ
Is BGMD a good stock?
Stock Expert AI does not rate BGMD buy, sell or hold. BG Medicine, Inc. has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the main risks for BGMD?
BG Medicine, Inc. faces several key risks. Competition from larger, more established players in the diagnostics market poses a significant threat.
What are the key factors to evaluate for BGMD?
Evaluate BGMD on fundamentals, analyst consensus, and risk factors. Investing in BG Medicine, Inc. presents a high-risk, high-reward scenario. Not financial advice.
How frequently does BGMD data refresh on this page?
BGMD's price was last updated on Sep 10, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven BGMD's recent stock price performance?
BG Medicine, Inc. (BGMD) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Specialized focus on cardiovascular diagnostics. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider BGMD overvalued or undervalued right now?
BG Medicine, Inc. (BGMD) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of BGMD?
Yes, most major brokerages offer fractional shares of BG Medicine, Inc. (BGMD) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track BGMD's earnings and financial reports?
BG Medicine, Inc. (BGMD) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for BGMD earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be less reliable than exchange-listed data.
- Financial data is limited and may not be fully up-to-date.